Frontiers in Viral Hepatitis

Frontiers in Viral Hepatitis

2003, Pages 335-351
Frontiers in Viral Hepatitis

Chapter 28 - Nomenclature for antiviral resistant human hepatitis B virus mutations in the polymerase region

https://doi.org/10.1016/B978-044450986-4/50079-5Get rights and content

Publisher Summary

An increasing number of treatment failures because of antiviral resistance have been recognized since the introduction of antiviral agents, such as lamivudine for the treatment of chronic hepatitis B virus (HBV) infections. There is currently no universally accepted numbering convention for the antiviral drug-related resistance mutations in the reverse transcriptase (rt) domain of the human HBV polymerase. The new system is based on functional observations of HBV surface gene proteins and the current convention used for HIV-1 polymerase proteins, in which the amino acid numbering restarts at the first codon position of each domain. The HBV polymerase protein can be divided into four domains and each of these can be numbered separately. The new consensus rt domain numbering system is genotype independent and allows investigators to number any previously and newly discovered antiviral-related amino acid change in a standardized manner.

References (0)

Cited by (0)

View full text